Biochem/physiol Actions
S 26948 belongs to the non-thiazolidinedione (TZD) class of drugs. It has the potential to treat diabetes and atherogenesis.
S 26948 is a selective PPARγ modulator (SPPARγM). S 26948 is as effective as rosiglitazone in reducing insulin resistance and lipid homeostasis, but does not increase body or white adipose tissue weight. S 26948 also leads to different co-activatior recruitment to PPARγ than rosiglitazone.
Features and Benefits
This compound is featured on the Nuclear Receptors (Non-Steroids) and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
- UPC:
- 85000000
- Condition:
- New
- HazmatClass:
- No
- MPN:
- SML0510-5MG
- CAS:
- 353280-43-0
akash.verma@cenmed.com
(732) 447-1115





